Opinion|Videos|April 25, 2025
Exploring Novel Options for the Management of Uncomplicated UTIs
Panelists discuss how sulopenem etzadroxil/probenecid, approved in October 2024, functions as an oral β-lactam/β-lactamase inhibitor effective against extended-spectrum β-lactamase producers per SURE 1 and REASSURE trial findings whereas gepotidacin works through a novel mechanism as a triazaacenaphthylene bacterial topoisomerase inhibitor targeting resistant pathogens via unique DNA gyrase and topoisomerase IV binding sites, with EAGLE trial findings demonstrating noninferiority to nitrofurantoin with approximately 90% cure rates.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In October 2024, sulopenem etzadroxil/probenecid received FDA approval for uncomplicated urinary tract infection (UTI) based on the SURE 1 and REASSURE data. What is the mechanism of action of this therapy, and what are some key efficacy and safety points to be shared?
- Another emerging therapy showing promise in addressing patients with recurrent UTIs is gepotidacin, based on the EAGLE-2 and EAGLE-3trial findings. How is gepotidacin’s mechanism of action different from the other 2 newly approved therapies?
What are some key points to share regarding the methodology and outcomes of the EAGLE trials?
Advertisement
Related to this article
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Follitropin Delta Achieves Ongoing Pregnancy in 64% Under Age 35
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5